Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Trial Profile

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs PolyPEPI 1018 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; First in man
  • Acronyms OBERTO
  • Sponsors Treos Bio
  • Most Recent Events

    • 22 Sep 2018 Planned number of patients changed from 10 to 15.
    • 22 Sep 2018 Planned End Date changed from 21 Dec 2018 to 21 Dec 2019.
    • 22 Sep 2018 Planned primary completion date changed from 9 Oct 2018 to 9 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top